Morgan, T.M., Boorjian, S.A., Buyyounouski, M.K., Chapin, B.F., Chen, D.Y.T., Cheng, H.H., et al. (2024) Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy after Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. Journal of Urology, 211, 526-532.
https://doi.org/10.1097/ju.0000000000003890

has been cited by the following article:

• TITLE: Research Progress of Systemic Immune Inflammatory Index in Prostate Cancer

  AUTHORS: Zhiwei Zhao, Shaoping Cheng

  KEYWORDS: Prostate Cancer, Systemic Immune Inflammatory Index, Prostate-Specific Antigen

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.10, October 24, 2024

  ABSTRACT: Prostate cancer has gradually risen to become the second most common cancer threatening men’s health, and prostate-specific antigen (PSA), as the main screening indicator for prostate cancer, has the defects of low specificity and insufficient diagnostic efficacy. As a novel inflammatory index based on neutrophil, lymphocyte and platelet counts, the systemic immune-inflammation index (SII) has recently become a more powerful biomarker for predicting the occurrence and progression of various malignancies. SII reflects the systemic inflammatory response of prostate cancer patients in a more balanced manner, and has higher predictive value than neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). High SII values are often associated with cancer progression and poor prognosis. This article reviews the research progress of SII in prostate cancer, in order to provide guidance for clinical practice.